Author:
Ge Yang,Mu Wei,Ba Qian,Li Jingquan,Jiang Yiguo,Xia Qiang,Wang Hui
Funder
National Natural Science Foundation of China
National Key R&D Program of China
Key Research Program
Shanghai supporting program
Technology Innovation Program of Shanghai Municipal Education Commission
Reference112 articles.
1. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial;Kudo;Lancet,2018
2. The immunology of hepatocellular carcinoma;Ringelhan;Nat. Immunol.,2018
3. Epithelial-to-Mesenchymal transition in hepatocellular carcinoma;Huaman;Future Oncol.,2018
4. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: a systematic review and meta‐analysis;Kulik;Hepatology,2017
5. Retracted: hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies;International;BioMed Res. Int.,2018
Cited by
52 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献